. Correction to "Benefit of axicabtagene ciloleucel vs chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy". Am J Hematol 2024 May 7. doi: 10.1002/ajh.27356.
PMID: 38712755